Real World Evidence Showing High Rates of Cardiovascular Events in NAFLD Patients Regardless of Liver Disease.

Challenge

NAFLD is increasingly recognized as a cardiovascular risk condition, but real-world data confirming the prevalence and burden of CV events across the full NAFLD spectrum—including in community practice settings—were absent, limiting the strength of evidence for CV endpoint inclusion in NAFLD trials.

Solution

The TARGET-NASH cohort was analyzed to characterize CV disease history and incident CV event rates across NAFL, NASH, and cirrhosis subgroups, with multivariable regression identifying independent risk factors for CV events in a large, prospectively followed real-world US population.

Impact

Demonstrating high and increasing CV event rates across the NAFLD spectrum—and identifying NAFLD severity as an independent CV risk predictor—provides regulatory and clinical evidence supporting the inclusion of CV composite endpoints in NAFLD trials and reinforces the cardiovascular value proposition for MASH therapies.